GlassScriptPhysician profile
Chrystene A Nguyen
NPI 1710123609
$3,878.10
in general payments reported to CMS, 2019-2025
23 companies · $31.26 in 2025
The $31.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $110 · 2021: $116 · 2022: $525 · 2023: $1,240 · 2024: $935 · 2025: $31.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $615.04 | 2023-2024 | Tezspire, Breztri, Fasenra |
| Gilead Sciences, INC. | $590.86 | 2019-2023 | Vemlidy |
| Lilly USA, LLC | $402.80 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $366.25 | 2019-2023 | Tezspire, Otezla |
| Regeneron Healthcare Solutions, INC. | $362.04 | 2022-2023 | Dupixent |
| Glaxosmithkline, LLC. | $277.80 | 2019-2024 | Nucala |
| Nevro Corp. | $176.21 | 2019 | |
| Genzyme Corporation | $173.88 | 2023-2024 | |
| Abiomed | $152.93 | 2023-2024 | Impella |
| Genentech USA, INC. | $131.37 | 2024 | Xolair |
| Ucb, INC. | $125.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $124.51 | 2024 | Voquezna |
| Endogastric Solutions, INC | $116.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.00 | 2022 | |
| Vifor Pharma, INC. | $34.90 | 2024 | Zemaira |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.30 | 2024 | Ofev |
| Novo Nordisk INC | $30.90 | 2024 | Rybelsus, Ozempic |
| United Therapeutics Corporation | $24.42 | 2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $22.79 | 2024 | Glassia |
| Grifols USA, LLC | $21.05 | 2024 | Prolastin-C Liquid |
| Zoll Respicardia, INC. | $16.96 | 2025 | Remede System |
| Exact Sciences Corporation | $15.48 | 2024 | Cologuard Collection Kit |
| Philips North America LLC | $14.30 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrystene Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.